New GLP-1 Drug Retatrutide Undergoes Clinical Evaluation | Retatrutide News

Retatrutide, a new GLP-1 agonist by Eli Lilly, is in clinical trials for metabolic conditions. This could represent a stronger option in GLP-1 therapies...
Clinical Trials · October 31, 2026